WallStSmart

Advanced Micro Devices Inc (AMD)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 61% more annual revenue ($60.44B vs $37.45B). AZN leads profitability with a 17.2% profit margin vs 13.4%. AMD appears more attractively valued with a PEG of 1.05. AZN earns a higher WallStSmart Score of 62/100 (C+).

AMD

Buy

61

out of 100

Grade: C+

Growth: 9.3Profit: 6.0Value: 4.3Quality: 9.0
Piotroski: 6/9Altman Z: 3.74

AZN

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 8.5Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AMD.

AZNUndervalued (+6.6%)

Margin of Safety

+6.6%

Fair Value

$220.34

Current Price

$182.85

$37.49 discount

UndervaluedFair: $220.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMD6 strengths · Avg: 9.7/10
Market CapQuality
$666.04B10/10

Mega-cap, among the largest globally

Revenue GrowthGrowth
37.8%10/10

Revenue surging 37.8% year-over-year

EPS GrowthGrowth
91.2%10/10

Earnings expanding 91.2% YoY

Debt/EquityHealth
0.0710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.7410/10

Safe zone — low bankruptcy risk

Free Cash FlowQuality
$2.57B8/10

Generating 2.6B in free cash flow

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$286.68B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
23.5%9/10

Every $100 of equity generates 24 in profit

Operating MarginProfitability
28.2%8/10

Strong operational efficiency at 28.2%

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

Areas to Watch

AMD2 concerns · Avg: 3.0/10
Price/BookValuation
11.8x4/10

Trading at 11.8x book value

P/E RatioValuation
137.1x2/10

Premium valuation, high expectations priced in

AZN3 concerns · Avg: 3.3/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AMD

The strongest argument for AMD centers on Market Cap, Revenue Growth, EPS Growth. Revenue growth of 37.8% demonstrates continued momentum. PEG of 1.05 suggests the stock is reasonably priced for its growth.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.

Bear Case : AMD

The primary concerns for AMD are Price/Book, P/E Ratio. A P/E of 137.1x leaves little room for execution misses.

Bear Case : AZN

The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.

Key Dynamics to Monitor

AMD profiles as a growth stock while AZN is a mature play — different risk/reward profiles.

AMD carries more volatility with a beta of 2.40 — expect wider price swings.

AMD is growing revenue faster at 37.8% — sustainability is the question.

AMD generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (62/100 vs 61/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Advanced Micro Devices Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Advanced Micro Devices, Inc. (AMD) is an American multinational semiconductor company based in Santa Clara, California, that develops computer processors and related technologies for business and consumer markets. AMD's main products include microprocessors, motherboard chipsets, embedded processors and graphics processors for servers, workstations, personal computers and embedded system applications.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?